CYCC - サイクラセル・ファ―マシュ―ティカルズ (Cyclacel Pharmaceuticals Inc.) サイクラセル・ファ―マシュ―ティカルズ

 CYCCのチャート


 CYCCの企業情報

symbol CYCC
会社名 Cyclacel Pharmaceuticals Inc (サイクラセル・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 サイクラセル・ファーマシューティカルズ(Cyclacel Pharmaceuticals Inc.)は開発段階にあるバイオ製薬企業であり、ヒト癌とその他重篤な疾患を治療するメカニズムをターゲットとした医薬品の発見・開発・商業化に従事する。同社は米国とイギリスの2つの地域において開発事業を行う。同社はサパシタビン(sapacitabine)とセリシクリブ(seliciclib)が含まれる細胞周期に作用する複数の抗癌剤シリーズを生成している。同社は主に細胞周期の進行を減速したり、腫瘍のサーズを小さくしたりすることを目的とする、経口投与可能な抗癌剤の開発を中心とする。同社の臨床開発は高齢者急性骨髄性白血病(AML)、骨髄異形成症候群(MDS)及び非小細胞肺癌(NSCLC)を含むサパシタビンを中心としている。同社は癌とその他重篤な疾患を治療するため、細胞周期制御における様々な段階をターゲットとする低分子薬の開発・商業化を行う。   サイクラセル・ファ―マシュ―ティカルズは米国のバイオ医薬品企業。臨床段階で、がん及びその他重症疾患向け治療薬の開発・商品化に従事する。経口投与可能で、細胞分裂を抑止する小分子治験薬のパイプラインを推進する。主力候補薬には、急性骨髄性白血病治療薬の「Sapacitabine」がある。本社はニュ―ジャ―ジ―州。   Cyclacel Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It uses cell cycle, transcriptional regulation and DNA damage response biology to develop medicines for cancer and other proliferative diseases. The company builds a biopharmaceutical business, which is focused in hematology and oncology based on a pipeline of novel drug candidates. Its products include CYC065, seliciclib, and sapacitabine. The company was founded by Ronald J. Berenson, David Philip Lane, and David Glover on August 13, 1996 and is headquartered in Berkeley Heights, NJ.
本社所在地 200 Connell Drive Suite 1500 Berkeley Heights NJ 07922 USA
代表者氏名 David Charles U'Prichard デビッドチャールズウプリアード
代表者役職名 Independent Chairman of the Board
電話番号 +1 908-517-7330
設立年月日 35065
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数 16人
url www.cyclacel.com
nasdaq_url https://www.nasdaq.com/symbol/cycc
adr_tso
EBITDA EBITDA(百万ドル) -8.90700
終値(lastsale) 1.39
時価総額(marketcap) 16676451.33
時価総額 時価総額(百万ドル) 16.31653
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) -3.50747
当期純利益 当期純利益(百万ドル) -14.30400
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Cyclacel Pharmaceuticals Inc revenues was not reported. Net loss applicable to common stockholders decreased 14% to $3.3M. Lower net loss reflects Research and Development - other decrease of 24% to $1.9M (expense) Interest income increase from $30K to $153K (income) Stock-based Compensation in SGA decrease of 14% to $85K (expense). Dividend per share remained flat at $0.15.

 CYCCのテクニカル分析


 CYCCのニュース

   Cyclacel Pharmaceuticals Investors Should Be Furious After This Move  2020/04/21 15:20:37 24/7 Wall street
   Nano-Cap Cyclacel Rockets Higher On Launch Of Study For Coronavirus Inflammation  2020/04/20 15:33:29 Benzinga
Shares of nanocap biopharma Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC ) were ripping higher Monday following the announcement of a partnership to study two of its drugs to treat complications arising from COVID-19. The company said it has entered into an agreement with the University of Edinburgh to study two of its pipeline assets — fadraciclib and seliciclib — as potential early treatments for the inflammatory response observed in patients with COVID-19 disease. Fadraciclib and seliciclib are both investigational CDK2/9 inhibitors in development. Cyclacel is studying the drugs for their suitability for use in safety and efficacy studies in COVID-19 patients. The … Full story available on Benzinga.com
   Cyclacel (CYCC) to Report Q4 Earnings: What's in the Cards?  2020/02/20 13:50:00 Zacks Investment Research
We expect Cyclacel (CYCC) to provide updates on its pipeline when it releases fourth-quarter 2019 results.
   Cyclacel Pharmaceuticals (CYCC) to Release Earnings on Wednesday  2019/11/11 11:35:22 Modern Readers
Cyclacel Pharmaceuticals (NASDAQ:CYCC) will be releasing its earnings data after the market closes on Wednesday, November 13th. Analysts expect Cyclacel Pharmaceuticals to post earnings of ($0.17) per share for the quarter. Persons interested in participating in the company’s earnings conference call can do so using this link. Cyclacel Pharmaceuticals (NASDAQ:CYCC) last released its quarterly earnings […]
   The Daily Biotech Pulse: Jazz Goes Shopping, Portola Offering, Novelion Delays Quarterly Results  2019/08/13 11:25:15 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 12) GENMAB A/S/S ADR (NASDAQ: GMAB ) (IPOed July 1) Down In The Dumps (Biotech stocks hitting 52-week lows on Aug. 13) Acer Therapeutics Inc (NASDAQ: ACER ) Aclaris Therapeutics Inc (NASDAQ: ACRS ) Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP ) Adial Pharmaceuticals Inc (NASDAQ: ADIL ) Advaxis, Inc. (NASDAQ: ADXS ) AnaptysBio Inc (NASDAQ: ANAB ) Autolus Therapeutics Ltd – ADR (NASDAQ: AUTL ) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC ) Fulcrum Therapeutics Inc (NASDAQ: FULC ) Gamida Cell Ltd (NASDAQ: GMDA ) GENFIT S A/ADR (NASDAQ: GNFT ) Hemispherx BioPharma, Inc (NYSE: HEB ) Homology Medicines Inc (NASDAQ: FIXX ) INmune Bio Inc (NASDAQ: INMB )(reacted to second quarter results) Innovate Biopharmaceuticals Inc (NASDAQ: INNT ) Mallinckrodt PLC (NYSE: MNK )(was accused by Humana Inc (NYSE: HUM ) of manipulating prices of Achtar) Mersana Therapeutics Inc (NASDAQ: MRSN ) Novavax, Inc. (NASDAQ: NVAX )(reported new data from the Phase 3 trial dubbed PREPARE that evaluated its ResVax ) Obalon Therapeutics Inc (NASDAQ: OBLN ) Pfizer Inc. (NYSE: PFE ) Plus Therapeutics Inc (NASDAQ: PSTV ) Proteostasis …
   Cyclacel (CYCC) to Report Q4 Earnings: What's in the Cards?  2020/02/20 13:50:00 Zacks Investment Research
We expect Cyclacel (CYCC) to provide updates on its pipeline when it releases fourth-quarter 2019 results.
   Cyclacel Pharmaceuticals (CYCC) to Release Earnings on Wednesday  2019/11/11 11:35:22 Modern Readers
Cyclacel Pharmaceuticals (NASDAQ:CYCC) will be releasing its earnings data after the market closes on Wednesday, November 13th. Analysts expect Cyclacel Pharmaceuticals to post earnings of ($0.17) per share for the quarter. Persons interested in participating in the company’s earnings conference call can do so using this link. Cyclacel Pharmaceuticals (NASDAQ:CYCC) last released its quarterly earnings […]
   The Daily Biotech Pulse: Jazz Goes Shopping, Portola Offering, Novelion Delays Quarterly Results  2019/08/13 11:25:15 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 12) GENMAB A/S/S ADR (NASDAQ: GMAB ) (IPOed July 1) Down In The Dumps (Biotech stocks hitting 52-week lows on Aug. 13) Acer Therapeutics Inc (NASDAQ: ACER ) Aclaris Therapeutics Inc (NASDAQ: ACRS ) Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP ) Adial Pharmaceuticals Inc (NASDAQ: ADIL ) Advaxis, Inc. (NASDAQ: ADXS ) AnaptysBio Inc (NASDAQ: ANAB ) Autolus Therapeutics Ltd – ADR (NASDAQ: AUTL ) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC ) Fulcrum Therapeutics Inc (NASDAQ: FULC ) Gamida Cell Ltd (NASDAQ: GMDA ) GENFIT S A/ADR (NASDAQ: GNFT ) Hemispherx BioPharma, Inc (NYSE: HEB ) Homology Medicines Inc (NASDAQ: FIXX ) INmune Bio Inc (NASDAQ: INMB )(reacted to second quarter results) Innovate Biopharmaceuticals Inc (NASDAQ: INNT ) Mallinckrodt PLC (NYSE: MNK )(was accused by Humana Inc (NYSE: HUM ) of manipulating prices of Achtar) Mersana Therapeutics Inc (NASDAQ: MRSN ) Novavax, Inc. (NASDAQ: NVAX )(reported new data from the Phase 3 trial dubbed PREPARE that evaluated its ResVax ) Obalon Therapeutics Inc (NASDAQ: OBLN ) Pfizer Inc. (NYSE: PFE ) Plus Therapeutics Inc (NASDAQ: PSTV ) Proteostasis …
   Cyclacel Pharmaceuticals, Inc. (CYCC) CEO Spiro Rombotis on Q1 2019 Results - Earnings Call Transcript  2019/05/14 23:21:33 Seeking Alpha
   Cash Dividend On The Way From Cyclacel Pharmaceuticals Convertible Exchangeable Preferred Stock  2019/04/10 19:06:00 Nasdaq
On 4 12 19 Cyclacel Pharmaceuticals Inc s 6 Convertible Exchangeable Preferred Stock Symbol CYCCP will trade ex dividend for its quarterly dividend of 0 15 payable on 5 1 19 As a percentage of CYCCP s recent share price of 5 17 this dividend works out to approximately 2 90 so look
   Cyclacel Pharmaceuticals (CYCC) to Release Earnings on Wednesday  2019/11/11 11:35:22 Modern Readers
Cyclacel Pharmaceuticals (NASDAQ:CYCC) will be releasing its earnings data after the market closes on Wednesday, November 13th. Analysts expect Cyclacel Pharmaceuticals to post earnings of ($0.17) per share for the quarter. Persons interested in participating in the company’s earnings conference call can do so using this link. Cyclacel Pharmaceuticals (NASDAQ:CYCC) last released its quarterly earnings […]
   The Daily Biotech Pulse: Jazz Goes Shopping, Portola Offering, Novelion Delays Quarterly Results  2019/08/13 11:25:15 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 12) GENMAB A/S/S ADR (NASDAQ: GMAB ) (IPOed July 1) Down In The Dumps (Biotech stocks hitting 52-week lows on Aug. 13) Acer Therapeutics Inc (NASDAQ: ACER ) Aclaris Therapeutics Inc (NASDAQ: ACRS ) Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP ) Adial Pharmaceuticals Inc (NASDAQ: ADIL ) Advaxis, Inc. (NASDAQ: ADXS ) AnaptysBio Inc (NASDAQ: ANAB ) Autolus Therapeutics Ltd – ADR (NASDAQ: AUTL ) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC ) Fulcrum Therapeutics Inc (NASDAQ: FULC ) Gamida Cell Ltd (NASDAQ: GMDA ) GENFIT S A/ADR (NASDAQ: GNFT ) Hemispherx BioPharma, Inc (NYSE: HEB ) Homology Medicines Inc (NASDAQ: FIXX ) INmune Bio Inc (NASDAQ: INMB )(reacted to second quarter results) Innovate Biopharmaceuticals Inc (NASDAQ: INNT ) Mallinckrodt PLC (NYSE: MNK )(was accused by Humana Inc (NYSE: HUM ) of manipulating prices of Achtar) Mersana Therapeutics Inc (NASDAQ: MRSN ) Novavax, Inc. (NASDAQ: NVAX )(reported new data from the Phase 3 trial dubbed PREPARE that evaluated its ResVax ) Obalon Therapeutics Inc (NASDAQ: OBLN ) Pfizer Inc. (NYSE: PFE ) Plus Therapeutics Inc (NASDAQ: PSTV ) Proteostasis …
   Cyclacel Pharmaceuticals, Inc. (CYCC) CEO Spiro Rombotis on Q1 2019 Results - Earnings Call Transcript  2019/05/14 23:21:33 Seeking Alpha
   Cash Dividend On The Way From Cyclacel Pharmaceuticals Convertible Exchangeable Preferred Stock  2019/04/10 19:06:00 Nasdaq
On 4 12 19 Cyclacel Pharmaceuticals Inc s 6 Convertible Exchangeable Preferred Stock Symbol CYCCP will trade ex dividend for its quarterly dividend of 0 15 payable on 5 1 19 As a percentage of CYCCP s recent share price of 5 17 this dividend works out to approximately 2 90 so look
   Cyclacel Announces Presentation of Phase 1 Data of Sapacitabine Regimen in Patients With BRCA Mutant Breast Cancer at AACR 2019  2019/04/01 11:00:00 Yahoo Finance
BERKELEY HEIGHTS, N.J., April 01, 2019 -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing.

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 サイクラセル・ファ―マシュ―ティカルズ CYCC Cyclacel Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)